Circulating tumor microemboli as a prognostic factor for locally advanced or metastatic solid tumors.

Corassa, Marcelo; Fanelli, Marcello Ferretti; Oliveira, Thiago Bueno; Mello, Celso Lopes; Netto, Marcelo Calil Machado; Braun, Alexcia Camila; Abdallah, Emne Ali; García, Daniel; Silva, Virgilio Sousa; Kowalski, Luiz Paulo; Alves, Vanessa da Silva; Chinen, Ludmilla T.D.

doi:10.1200/jco.2016.34.15_suppl.e23067

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it was our first study with DT, we have extensive experience with ISET, as we have been working with this method for a long time, with many published papers (29,(32)(33)(34)(35)(36)(37)(38)(39)(40) including two with sarcomas (29,41). In the first paper with sarcoma (29), we tested the sensitivity of the method, as we were the first group to test ISET for non-solid tumors, and we proved, with cell line, that its sensitivity was high, even for mesenchymal cells.…”

Section: Discussionmentioning

confidence: 99%

“…Knowledge regarding CTMs, also called CTC clusters, has evolved over the last decade, and increasing evidence suggests that they play an essential role on the pathophysiology of metastasis (44). Preclinical and clinical studies exploiting other cancers have demonstrated that CTMs are associated with increased metastatic potential and poor prognosis (36,(45)(46)(47)(48). Hayashi et al detected CTMs in sarcoma patients using CellSieve ™ , a low-pressure microfiltration device.…”

Section: Figure 1 | (A-f)mentioning

confidence: 99%

See 1 more Smart Citation

Circulating Tumor Cells in Desmoid Tumors: New Perspectives

et al. 2021

View full text Add to dashboard Cite

IntroductionDesmoid tumor (DT) is a rare neoplasm with high local recurrence rates, composed of fibroblastic cells that are characterized by the expression of key molecules, including the intermediate filament vimentin, cyclooxygenase-2 (COX-2), and nuclear β-catenin, and lack of epithelial markers. Circulating tumor cells (CTCs) isolated from the peripheral blood of patients with sarcomas and other neoplasms can be used as early biomarkers of tumor invasion and dissemination. Moreover, CTCs can also re-colonize their tumors of origin through a process of “tumor self-seeding.”ObjectivesWe aimed to identify CTCs in the peripheral blood of patients with DT and evaluate their expression of β-catenin, transforming growth factor receptor I (TGF-βRI), COX-2, and vimentin proteins.Material and MethodsWe conducted a prospective study of patients with initial diagnosis or relapsed DT with measurable disease. Blood samples from each patient were processed and filtered by ISET® (Rarecells, France) for CTC isolation and quantification. The CTC expression of β-catenin, COX-2, TGF-βRI, and vimentin was analyzed by immunocytochemistry (ICC).ResultsA total of 18 patients were included, and all had detectable CTCs. We found a concordance of β-catenin expression in both CTCs and primary tumors in 42.8% (6/14) of cases by using ICC and immunohistochemistry, respectively.ConclusionsOur study identified a high prevalence of CTCs in DT patients. Concordance of β-catenin expression between primary tumor and CTCs brings new perspectives to assess the dynamics of CTCs in the blood compartment, opening new avenues for studying the biology and behavior of DT. In addition, these results open the possibility of using CTCs to predict DT dynamics at the time of disease progression and treatment. Further studies with larger sample sizes are needed to validate our findings.

show abstract